Brief: Basilea Pharmaceutica FY Operating Income CHF 19.2 Million
13/02/2024 06:17
Feb 13 (Reuters) - Basilea Pharmaceutica FY basic EPS CHF 0.86. * FY net income CHF 10.5 million * FY operating expenses CHF -138.4 million * FY operating income CHF 19.2 million
Recent news on Basilea Pharmaceutica AG, Allschwil
See all newsBrief: Basilea Pharmaceutica - Strong Cresemba Sales In Europe Trigger USD 37.5 Mln Milestone Payment
Basilea seen up after raising 2026 guidance
Brief: Basilea Expects 2026 Operating Profit Of CHF 115 Mln
Brief: Basilea Reports Presentation Of New Data For Fosmanogepix, Isavuconazole And Ceftobiprole At IDWeek 2026
RCS - Accession Theraptcs. - Accession Therapeutics: Board appointments